Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

Autor: Paul, O'Connor, Wolinsky, Jerry S., Christian, Confavreux, Giancarlo, Comi, Ludwig, Kappos, Olsson, Tomas P., Hadj, Benzerdjeb, Philippe, Truffinet, Lin, Wang, Aaron, Miller, Temso Trial Group Reingold, Freedman Ms S., Cutter, G., Antel, J., Barkhof, F., Maddrey, W., Ravnborg, M., Schenker, S., O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Miller, A., Freedman, Mark S., Narayana, P. A., Nelson, F., Vainrub, I., Datta, S., He, R., Gates, B., Ton, K., Wamil, B., Truffinet, P., Igau, B., Nicolas, V., Notelet, L., Payrard, S., Wijnand, P., Devore, S., H. H., Li, Osho, T., Wang, L., Wei, L., Dukovic, D., Ling, Y., Benzerdjeb, H., Mednikova, Z., Trabelsi, N., Musset, M., Merrill, D., Turpault, S., Williams, B., Nortmeyer, H., Kirst, E., Witthaus, E., Chen, S., Maida, E., Auff, E., Fazekas, F., Berger, T., Bhan, V., Bouchard, J. P., Duquette, P., Freedman, M., Grand'Maison, F., Kremenchutzky, M., Bourque, C., Marrie, R. A., Melanson, M., Patry, D., Oger, J., Stefanelli, M., Jacques, F., Venegas, P., Miranda, M., Barrientos, N., Tenhamm, E., Gloger, S., Rohde, G., Mares, J., Frederiksen, J., Stenager, E., Haldre, S., Gross Paju, K., Elovaara, I., Sumelahti, M. L., Erälinna, J. P., Farkkila, M., Harno, H., Reunanen, M., Jolma, T., Camu, W., Clavelou, P., Magy, L., Debouverie, M., Edan, G., Lebrun Frenay, C., Moreau, T., Pelletier, J., Roullet, E., Alamowitch, S., Clanet, M., Hautecoeur, P., Damier, P., Rumbach, L., Chan, A., Schimrigk, S., Haas, J., Lensch, E., Diener, H., Limmroth, V., Anders, D., Berghoff, M., Oschmann, P., Stangel, M., Frese, A., Kiefer, R., Marziniak, M., Zettl, U., Stark, E., Jendroska, K., Reifschneider, G., Amato, M. P., Cosi, V., Gallo, P., Gasperini, Claudio, Ghezzi, A., Trojano, M., Pozzilli, Carlo, Montanari, E., Zwanikken, C. P., Jongen, P. J., Van Munster, E. T., Hupperts, R. M., Anten, B., Sanders, E. A., Celius, E., Hovdal, H., Krogseth, S. B., Kozubski, W., Kwiecinski, H., Czlonkowska, A., Stelmasiak, Z., Selmaj, K., Hasiec, T., Fryze, W., Drozdowski, W., Kochanowicz, J., Cunha, L., De Sa, J., Sena, A. H., Odinak, M., Skoromets, A., Gusev, E., Boiko, A., Lashch, N., Stolyarov, I., Belova, A., Malkova, N., Doronin, B., Yakupov, E., Brundin, L., Hillert, J., Karabudak, R., Irkec, C., Idiman, E., Turan, O., Efendi, H., Gedizlioglu, M., Buchakchyyska, N., Goloborodko, A., Ipatov, A., Kobets, S., Lebedynets, V., Moskovko, S., Sanotskyy, Y., Smolanka, V., Yavorskaya, V., Bates, D., Evangelou, N., Hawkins, C., Mclean, B., O'Riordan, J., Price, S., Turner, B., Barnes, D., Zajicek, J., Honeycutt, W., Khan, O., Spikol, L., Stevens, J.

Publikováno v: Wolinsky, J S, Confavreux, C, Comi, G, Kappos, L, Olsson, T P, Benzerdjeb, H, Truffinet, P, Wang, L, Miller, A E, Freedman, M S, Stenager, E & Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group 2011, ' Randomized trial of oral teriflunamide for relapsing multiple sclerosis ', The New England Journal of Medicine, vol. 2011, no. 365, pp. 1293-1303 . https://doi.org/10.1056/NEJMoa1014656
New England Journal of Medicine, 365(14), 1293-1303. MASSACHUSETTS MEDICAL SOCIETY

Teriflunomide reduced the annualized relapse rate (0.54 for placebo vs. 0.37 for teri flunomide at either 7 or 14 mg), with relative risk reductions of 31.2% and 31.5%, respectively (P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea72b10598dc98c42c6663d5f5508b91
https://doi.org/10.1056/nejmoa1014656

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial

Autor: Ludwig Kappos, M. S. Freedman, G. Comi, Jerry S. Wolinsky, Aaron E. Miller, B. Wamil, Hadj Benzerdjeb, Christian Confavreux, Tomas Olsson, C. Simonson, Paul O'Connor, H. Li

Publikováno v: Neurology. 78(23)

To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS).A total of 118 patients with RMS were randomly assigned 1:1:1 to receive oral placebo or teriflunom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca6f74826e487ccbd2027ae66c36f98a
https://pubmed.ncbi.nlm.nih.gov/22622860

Pregnancy Outcomes from the Teriflunomide Clinical Development Program: Retrospective Analysis of a Global Pharmacovigilance Database (P06.190)

Autor: Bernd C. Kieseier, Myriam Benamor, Hadj Benzerdjeb, Olaf Stüve

Publikováno v: Neurology. 78:P06.190-P06.190

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b4f8b42495a087956cbc0a774fa9231
https://doi.org/10.1212/wnl.78.1_meetingabstracts.p06.190